头孢洛扎-他唑巴坦治疗血液恶性肿瘤和造血细胞移植受者中多重耐药铜绿假单胞菌感染。
Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mail Code L457, Portland, OR, 97239, USA.
Department of Pharmacy, Oregon Health and Science University, Portland, OR, USA.
出版信息
Infection. 2018 Jun;46(3):431-434. doi: 10.1007/s15010-018-1125-5. Epub 2018 Feb 19.
Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.
耐多药（MDR）铜绿假单胞菌感染导致血液系统恶性肿瘤患者和造血细胞移植受者的死亡率显著增加。头孢他洛滨-他唑巴坦（C-T）是治疗耐多药铜绿假单胞菌感染的一种新的治疗选择，但此类患者的临床经验有限。我们报告了使用 C-T 单药治疗这些患者人群的侵袭性耐多药铜绿假单胞菌感染的良好临床结果，且无明显毒性。
Zotero 插件